Reproductive reunion

Investors in ObsEva S.A., the latest spinout from the Merck Serono unit of Merck KGaA (Xetra:MRK), see the newco as an opportunity to reunite with management that previously found success in the reproductive health space.

Late last month, ObsEva raised CHF32 million ($34.7 million) in a series A round led by Sofinnova Partners, Sofinnova Ventures and Novo A/S. ObsEva also in-licensed exclusive, worldwide rights to undisclosed Merck Serono compounds to prevent preterm labor. Merck Serono's corporate VC fund, MS Ventures, received an undisclosed minority stake in the deal...